{
    "nctId": "NCT02118636",
    "briefTitle": "Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms",
    "officialTitle": "Prospective Observational Study of Breast Cancer Patients Starting Therapy With an AI to Evaluate Mechanisms Underlying Development of Aromatase Inhibitor Associated Musculoskeletal Symptoms",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Arthralgia",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Change in estradiol and development of musculoskeletal symptoms between baseline and 3 months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage I-III breast cancer who are scheduled to receive endocrine therapy with an aromatase inhibitor\n* All prior surgery, chemotherapy, and radiation therapy should be complete or should be completed by the time of AI treatment initiation (within 28 days of study enrollment)\n* Age 21 and above and postmenopausal",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}